Ken joined Prosonix' Board of Directors as a Director in August 2011 and became Non-executive Chairman in November 2012. He is also the Chair of the Advisory Board. Ken has over 20 years' experience in the pharmaceutical industry. He is Executive Chairman of PolyTherics Ltd and until August 2010 was CEO of Skyepharma plc. Before that he was Chief Executive Officer of Arakis Ltd, Vice-President European Affairs at Alza Corporation and Vice-President Clinical Development at Sequus Inc. Prior to this he held a variety of clinical development and commercial strategy roles at GlaxoWellcome plc and Warner-Lambert earlier in his career. Ken is also a Non-Executive Director of Xention Ltd. He holds a medical degree from St Mary's, Imperial College, London University.
David is a co-founder of Prosonix and has led the Company as CEO since its establishment in 2006, raising more than £22 million from international life sciences investors. Prior to Prosonix, he was General Manager of the C3 Technology Business of Accentus, which he established after joining them in 2002. David has more than 20 years of business development experience concerning cutting-edge technologies in high growth, complex, intellectual property-rich environments, with a prime focus on the pharmaceutical industry. He has also held a number of senior positions in Dow Pharma, Ascot plc, ChiroTech Ltd, and Air Products plc. David holds a BSc in Chemical Engineering.
Andy is a co-founder of Prosonix and, as COO/CFO, has managed the establishment, development and profitable growth of the business since formation in 2006 to deliver key strategic elements of the business plan. Andy has nearly 25 years' experience in international business management, including both operational capability development and financial control, while supporting major commercial deal making. Prior to joining Prosonix, he was Operations Manager of the C3 Technology Business of Accentus and previously held senior positions in two AEA Technology businesses in change management and business transformation roles. Before that he enjoyed a highly successful 18-year career in BOC spanning technical, operations and commercial management and was responsible for winning several long-term, multi-million pound business contracts. Andy holds a Bachelors' Degree in Chemical Engineering and is a Chartered Engineer. He also holds a Masters' Degree in Business Administration.
Karl joined Gimv in 2011 and is a Venture Capital Partner in the Life Sciences team. Prior to joining Gimv he worked as General Partner with Ventech, a Paris-based Europe and China focused VC fund where he led investments into Covagen, Funxional Therapeutics, Themis and Prosonix and served on the boards of those companies. He also served on the board of Actogenix. Between 2002 and 2009, Karl was at Atlas Venture (London and Munich), a transatlantic venture fund, where he was instrumental in the formation and/or financing of several start-ups across Europe, including U3 Pharma (acquired by Daiichi Sankyo) and Nitec Pharma (acquired by Horizon Pharma). Previously, he worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg (France). Karl holds a PhD in molecular neurobiology from the Max-Delbrück-Center for Molecular Medicine Berlin (Germany) and a diploma in Biology from the Free University of Berlin.
Jean has held various senior positions in pharmaceutical and biotech companies during a 20-year international career. He is currently CEO of Euroscreen (Belgium), which he joined in 2006.
Jean joined the pharmaceutical industry after gaining his PharmD in Pharmacy from the University of Marseille, France, and his PhD in pharmacokinetics and metabolism from INSERM, the French public research organisation. He has since held senior positions with Sanofi (Montpellier, France), where he led the human pharmacokinetics, metabolism and preclinical safety activities for the overall pipeline of development programmes; he was also specifically responsible for pharmacological and metabolic investigations for Plavix® (clopidogrel). Then, with Galderma, he had senior positions in project management and drug development, and was based successively in Sophia Antipolis, France, and in Princeton, NJ, USA.
Prior to joining Euroscreen, Jean was VP Pharmaceutical Development of Proteus (Nimes, France), and then Chairman and CEO of Entomed (Strasbourg, France). He is also a consultant and member of the Consultative Committee for Inserm Transfert Initiative, which provides support for biotech company creation and seed funding.
Jean was appointed to serve as a director representative of Ventech on the Board of Prosonix in 2012.
Edwin is a Senior Partner at Gilde Investment Management, which he joined in 1997. He became investment manager of Gilde Strategic Situations Fund - a fund of funds - and was involved with investments in funds managed by AXA (France), Amadeus (UK), Technologie Holding (now 3i, Germany) and OneLiberty Ventures (now Flagship Ventures, US). In 1998 he was appointed investment manager and later investment director of Gilde Healthcare I. Edwin received EVCJ's "Venture Realization of the Year - Life Science award" in 2005 for the sale of GlycArt to Roche. Previously, he served for three years as a tax consultant in the International Tax department of Coopers & Lybrand in the Netherlands, specializing in VAT. Edwin holds a Masters' Degree in Business and Fiscal Economics from Erasmus University in Rotterdam.
Klaas is the Managing Partner of the Entrepreneurs Fund, which he joined in 2006. He previously created and led a corporate venturing team at Vanenburg Group whose investments included WebEx, afterwhich he spent time as a consultant with McKinsey & Company in both Amsterdam and St Petersburg. Klaas has an MSc in Physics and an MBA from Insead.